Post-effective amendment to a registration statement that is not immediately effective upon filing

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)

v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($)
$ in Thousands
Convertible Series A Preferred Stock [Member]
Convertible Series B-1A Preferred Stock [Member]
Convertible Series B-1 Preferred Stock [Member]
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Retroactive application of reverse recapitalization $ (1)   $ (1) $ 31 $ (21)   $ 8
Retroactive application of reverse recapitalization (in shares) (1,000,000) (316,848) (1,050,695) 30,563,009      
Balance (as previously reported) at Dec. 31, 2019 $ 1   $ 1 $ 11 33,539 $ (38,403) (4,851)
Balance (as previously reported) (in shares) at Dec. 31, 2019 1,000,000 316,848 1,050,695 10,686,191      
Beginning balance at Dec. 31, 2019       $ 42 33,518 (38,403) (4,843)
Beginning balance (in shares) at Dec. 31, 2019       41,249,200      
Common stock issued         2,579   2,579
Common stock issued (in shares)       542,875      
Series B-2 convertible preferred stock issued         50   50
Series B-2 convertible preferred stock issued (in shares)       13,168      
Common stock issued to settle note conversion       $ 1 3,961   $ 3,962
Common stock issued to settle note conversion (in shares)       1,138,199     1,138,199
Common stock issued to settle accounts payable         145   $ 145
Common stock issued to settle accounts payable (in shares)       30,020      
Warrants issued as compensation for services         5,383   5,383
Stock-based compensation         730   730
Net income (loss)           (51,777) (51,777)
Ending balance at Dec. 31, 2020       $ 43 46,366 (90,180) (43,771)
Ending balance (in shares) at Dec. 31, 2020       42,973,462      
Common stock issued       $ 1 9,623   $ 9,624
Common stock issued (in shares)       915,454      
Proceeds from issuance of common stock for exercise of warrant (in shares)             516,025
Reclassification of settlement liability upon issuance of warrant         60,852   $ 60,852
Effect of Merger and recapitalization, net of redemptions and issuance costs       $ 2 (26,618)   (26,616)
Effect of Merger and recapitalization, net of redemptions and issuance costs (in shares)       2,529,730      
Common stock issued pursuant to PIPE financing, net of issuance costs       $ 1 8,099   8,100
Common stock issued pursuant to PIPE financing, net of issuance costs (in shares)       1,000,000      
Common stock issued for advisor services         4,850   4,850
Common stock issued for advisor services (in shares)       200,000      
Modification of option awards pursuant to Merger         1,015   1,015
Modification of warrants pursuant to Merger         2,330   2,330
Common stock and warrants issued in private placement, net of issuance costs       $ 3 27,356   27,359
Common stock and warrants issued in private placement, net of issuance costs (in shares)       2,727,273      
Issuance of common stock for exercise of warrants and Unit Purchase Options       $ 4 16,695   $ 16,699
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)       3,830,586     3,830,586
Common stock issued for consulting services       $ 5 48,982   $ 48,987
Common stock issued for consulting services (in shares)       4,634,045     4,834,045
Stock-based compensation         4,440   $ 4,440
Net income (loss)           (93,063) (93,063)
Ending balance at Dec. 31, 2021       $ 59 $ 203,990 $ (183,243) $ 20,806
Ending balance (in shares) at Dec. 31, 2021       58,810,550